A BSTRACT Lateral flow immunoassay (LFIA) is a widely recognized point-of-care diagnostic platform for detecting various analytes. It must meet the criteria of REASSURED, but poor sensitivity and lack of precision in test results remain the main bottlenecks of LFIA. Therefore, signal enhancement methods, such as devices, nanoprobes, or detection modes, can improve this platform. In this paper, many representative studies from the past decade on LFIA sensing platforms will be discussed in detail.
Chen et al. (Thu,) studied this question.